[WCN21;174;377]

New Therapies For MND

Pamela Shaw

Professor Dame Pamela Shaw is Professor of Neurology at the University of Sheffield and Director of: the Sheffield Institute for Translational Neuroscience (SITraN); the NIHR Sheffield Biomedical Research Centre; the Sheffield MND Care and Research Centre and the cross-faculty Neuroscience Institute.

She is a Clinician Scientist in Neurology, formerly Wellcome Trust Senior Fellow and currently NIHR Senior Investigator. Her team investigates genetic, molecular and neurochemical mechanisms underlying ALS/MND; investigates new therapeutic targets and translates new neuroprotective and symptomatic treatment approaches into the clinic, including genetic therapy approaches. She has active programmes in systematic biosample collection, biomarker discovery and subclassification of ALS. She is also spear-heading investigation of the role of environmental factors in ALS, including physical exercise. She has authored more than 520 publications (H-index 108).

Her research is funded by the MRC, Wellcome Trust, NIHR, MND Association, EU and biotech/pharmaceutical industry partners. She established and led (2009-2016) the national UK Clinical Studies Group for ALS/MND, a clinical research and trials network which links 20 UK ALS/MND Care and Research Centres.

Prof. Shaw has taken part in more than 23 ALS clinical trials, including roles as Chief Investigator and Steering Committee member and also including several academic led studies.